1. Home
  2. NA vs RVPH Comparison

NA vs RVPH Comparison

Compare NA & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NA

Nano Labs Ltd

HOLD

Current Price

$3.19

Market Cap

98.5M

Sector

Technology

ML Signal

HOLD

Logo Reviva Pharmaceuticals Holdings Inc.

RVPH

Reviva Pharmaceuticals Holdings Inc.

HOLD

Current Price

$0.31

Market Cap

71.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NA
RVPH
Founded
2019
2006
Country
China
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
98.5M
71.0M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
NA
RVPH
Price
$3.19
$0.31
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$3.33
AVG Volume (30 Days)
150.5K
7.9M
Earning Date
08-15-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,369,693.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.75
$0.25
52 Week High
$31.48
$2.17

Technical Indicators

Market Signals
Indicator
NA
RVPH
Relative Strength Index (RSI) 39.02 29.72
Support Level $2.98 $0.25
Resistance Level $3.46 $0.63
Average True Range (ATR) 0.17 0.07
MACD 0.06 -0.04
Stochastic Oscillator 49.55 11.40

Price Performance

Historical Comparison
NA
RVPH

About NA Nano Labs Ltd

Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: